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were 24,600, 26,800, 3,800, 2,700 and 3,210 respec-
tively. CONCLUSIONS: In terms of relapse rates Olan-
zapin and Flupentixol lead to better clinical outcome and
better cost-effectiveness results as compared to alterna-
tive typical or atypical neuroleptic therapy. With Olanza-
pin and Risperidon most favorable BPRS scores were
achieved. Flupentixol depot as monotherapy or following
initial Olanzapin treatment is a cost-effective alternative
to atypical neuroleptics at low drug cost and low relapse
rates.
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OBJECTIVES: Approximately one-half of patients with
an episode of major depression will have a recurrent epi-
sode during their lifetime. Recent studies indicate that ap-
proximately 20% of depressed patients are resistant to
traditional antidepressant treatments. This study utilizes
medical and prescription claims data from the 1995–
1998 MarketScan® Databases to profile the characteris-
tics and health care utilization of patients with treatment-
resistant depression. METHODS: Depression-diagnosed
patients with adequate antidepressant dosing and treat-
ment duration are selected. Patients are classified as treat-
ment-resistant if they have switched/augmented their ini-
tial medication with other antidepressants twice, or if
they have switched/augmented their initial medication
and have claims for depression-related hospitalizations or
suicide attempts. Depression-diagnosed patients meeting
selection criteria but not classified as treatment-resistant
by the above criteria are used as a comparison group.
RESULTS: Patients with treatment-resistant depression
are at least twice as likely to be diagnosed with bipolar
disorder, at least 1.5 times as likely to be diagnosed with
comorbid anxiety disorders, and at least 1.5 times as
likely to be diagnosed with substance-related disorders
than the comparison group (p-values 0.01). Patients
with treatment-resistant depression have 30% higher
mean number of psychiatric diagnostic groupings (PDG)
and 9% higher mean number of major diagnostic catego-
ries (MDC) than the comparison group (p-values 0.01).
Furthermore, patients with treatment-resistant depres-
sion are at least twice as likely to be hospitalized (depres-
sion and non-depression related), and have 41% more
outpatient visits than the comparison group (p-values
0.01). Finally, patients with treatment-resistant depres-
sion use 2 to 3 times more psychotropic medications (in
addition to antidepressants) than the comparison group
(p-values 0.01). CONCLUSIONS: Treatment-resistant
patients are higher utilizers of both depression-related
and general medical services. This finding underscores
the importance of early identification and effective treat-
ment of treatment-resistant patients to prevent future de-
pressive episodes and to mitigate health care utilization.
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OBJECTIVES: Health care utilization for patients with
bipolar disorder has received limited attention. This
study utilizes medical and prescription claims data from
the 1998 to mid-2000 MarketScan Databases to examine
the risks of hospitalization, a major cost driver in treating
bipolar patients. Hospitalizations are associated with a
relapse of bipolar symptoms (often due to treatment inef-
fectiveness or discontinuation). METHODS: Bipolar pa-
tients are identified using diagnosis codes and prescrip-
tion drug claims. An ‘intent-to-treat’ framework for
classifying drug cohorts by initial bipolar prescription is
used. Prescription claims are studied over a minimum of
a six-month time period to analyze drug use patterns
(e.g., switching and augmenting treatment). Descriptive
profiles of the bipolar patients are presented. Cox pro-
portional hazard models are used to examine the rela-
tionships among observable patient characteristics, drug
choice, drug use patterns, and hospitalizations. This
method accounts for the potential bias in parameter esti-
mates due to data censoring. RESULTS: Among patients
with at least 6-months of follow-up data (n  6,536), the
mean age is 43 years old and 63.3% are female. The
majority of patients are initially observed on antimanic
medications, with lesser percentages on other common
pharmacological therapies (typical and atypical antipsy-
chotics, and antiepileptics). During the 6-month follow-
up, 14.5% of patients have at least one hospitalization
and 7.2% have at least one bipolar-related hospitaliza-
tion. During a 12-month follow-up, 23.3% have at least
one hospitalization of any type and 11.5% have at least
one bipolar-related hospitalization. The unadjusted risk
of hospitalization increases over time, at a decreasing
rate. CONCLUSION: The high incidence of hospitaliza-
tion demonstrates the need for effective treatment op-
tions. This study also illustrates the importance of ac-
counting for censored data to obtain unbiased estimates
of factors associated with the risk of hospitalization.
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OBJECTIVES: Use of benzodiazepines in elderly patients
has been associated with adverse outcomes including mo-
